PlainRecalls
FDA Drug Moderate Class II Ongoing

Amlodipine and Valsartan Tablets USP 5 mg/160 mg, 30-count bottles, Rx Only, Manufactured for: Aurobindo Pharma USA, Inc., Dayton, NJ 08810. NDC 65862-737-30

Reported: January 23, 2019 Initiated: December 31, 2018 #D-0361-2019

Product Description

Amlodipine and Valsartan Tablets USP 5 mg/160 mg, 30-count bottles, Rx Only, Manufactured for: Aurobindo Pharma USA, Inc., Dayton, NJ 08810. NDC 65862-737-30

Reason for Recall

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Details

Recalling Firm
Aurobindo Pharma USA Inc.
Units Affected
18,408 bottles
Distribution
Product was distributed to 25 distributors and Retail Chains who may have further distributed the product throughout the United States.
Location
East Windsor, NJ

Frequently Asked Questions

What product was recalled?
Amlodipine and Valsartan Tablets USP 5 mg/160 mg, 30-count bottles, Rx Only, Manufactured for: Aurobindo Pharma USA, Inc., Dayton, NJ 08810. NDC 65862-737-30. Recalled by Aurobindo Pharma USA Inc.. Units affected: 18,408 bottles.
Why was this product recalled?
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 23, 2019. Severity: Moderate. Recall number: D-0361-2019.